Intracellular Pharmacokinetics of Cytosine Arabinoside in Leukemic and Normal Blood Cells

[1]  W. Hiddemann,et al.  High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison. , 1990, Cancer treatment reviews.

[2]  K. Bhalla,et al.  The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture. , 1990, Experimental hematology.

[3]  E. Estey,et al.  Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Bhalla,et al.  Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. , 1988, Leukemia.

[5]  E. Estey,et al.  Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. , 1987, Leukemia.

[6]  K. Bhalla,et al.  Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. , 1987, Blood.

[7]  H. Preisler,et al.  Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. , 1987, Seminars in oncology.

[8]  E. Estey,et al.  Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. , 1987, Seminars in oncology.

[9]  G. Hortobagyi.  Mitomycin-C in breast cancer. , 1985, Seminars in oncology.

[10]  W. Hiddemann,et al.  Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jan Liliemark,et al.  Relationship of 1-β-d-Arabinofuranosylcytosine in Plasma to 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Levels in Leukemic Cells during Treatment with High-Dose 1-β-d-Arabinofuranosylcytosine , 1985 .

[12]  H. Preisler,et al.  Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C). , 1985, Seminars in oncology.

[13]  E. Estey,et al.  Pharmacologically directed design of leukemia therapy. , 1990, Haematology and blood transfusion.

[14]  W. Hiddemann,et al.  Detection and separation of intracellular 1-beta-D-arabinofuranosylcytosine-5-triphosphate by ion-pair high-performance liquid chromatography. , 1989, Journal of chromatography.

[15]  E. Estey,et al.  Pharmacologically directed ara-C therapy for refractory leukemia. , 1985, Seminars in oncology.

[16]  G. Heinzel,et al.  [Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models (author's transl)]. , 1977, Arzneimittel-Forschung.